- Home
- BMY vs GILD Comparison
BMY vs GILD Comparison
Compare BMY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMY
- GILD
- Stock Information
- Founded
- BMY 1887
- GILD 1987
- Country
- BMY United States
- GILD United States
- Employees
- BMY N/A
- GILD N/A
- Industry
- BMY Biotechnology: Pharmaceutical Preparations
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMY Health Care
- GILD Health Care
- Exchange
- BMY Nasdaq
- GILD Nasdaq
- Market Cap
- BMY 120.5B
- GILD 138.2B
- IPO Year
- BMY N/A
- GILD 1992
- Fundamental
- Price
- BMY $59.59
- GILD $111.89
- Analyst Decision
- BMY Hold
- GILD Buy
- Analyst Count
- BMY 14
- GILD 27
- Target Price
- BMY $58.00
- GILD $105.32
- AVG Volume (30 Days)
- BMY 12.2M
- GILD 9.9M
- Earning Date
- BMY 04-24-2025
- GILD 04-24-2025
- Dividend Yield
- BMY 4.16%
- GILD 2.82%
- EPS Growth
- BMY N/A
- GILD N/A
- EPS
- BMY N/A
- GILD 0.38
- Revenue
- BMY $48,300,000,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- BMY N/A
- GILD $1.77
- Revenue Next Year
- BMY N/A
- GILD $3.52
- P/E Ratio
- BMY N/A
- GILD $294.45
- Revenue Growth
- BMY 7.32
- GILD 6.04
- 52 Week Low
- BMY $39.35
- GILD $62.07
- 52 Week High
- BMY $63.33
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- BMY 50.17
- GILD 57.09
- Support Level
- BMY $58.23
- GILD $109.60
- Resistance Level
- BMY $61.64
- GILD $112.86
- Average True Range (ATR)
- BMY 1.45
- GILD 2.38
- MACD
- BMY -0.16
- GILD -0.21
- Stochastic Oscillator
- BMY 39.74
- GILD 83.03
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).